Mesoblast Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MESO Nasdaq 2830 www.mesoblast.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mesoblast Limited

ASX Growth Companies With High Insider Ownership - May 31st, 2026 1:38 pm
ASX Penny Stocks With Market Caps Under A$3B To Consider - May 27th, 2026 9:05 pm
ASX Stocks Trading At An Estimated Discount Of Up To 45.8% Below Intrinsic Value - May 13th, 2026 1:34 pm
How Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment Story - May 1st, 2026 4:19 pm
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - Apr 29th, 2026 6:55 pm
ASX Penny Stocks To Watch In April 2026 - Apr 29th, 2026 2:02 pm
ASX Growth Companies With High Insider Ownership In April 2026 - Apr 29th, 2026 1:38 pm
Assessing Mesoblast’s Valuation After Recent Share Price Weakness And Conflicting Growth Signals - Apr 28th, 2026 8:08 pm
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain - Apr 28th, 2026 6:53 pm
Mesoblast Ltd (MESO): Secure Exclusive Rights to a Vital Platform - Apr 28th, 2026 11:30 am
Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in - Apr 19th, 2026 6:11 pm
Mesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See Why - Apr 19th, 2026 11:35 am
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products - Apr 14th, 2026 6:10 pm
Gregory George Adds To Mesoblast Position With Multi-Market Share Purchases - Apr 12th, 2026 4:52 pm
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION - Apr 10th, 2026 2:09 pm
Mesoblast (ASX:MSB) Is Down 11.0% After FDA Clears Registrational DMD Trial For Ryoncil - Has The Bull Case Changed? - Apr 8th, 2026 10:30 pm
Mesoblast R&D Day: Ryonsel Gains Traction, Back Pain Phase III Nears Finish, New Shots on Goal - Apr 8th, 2026 12:06 pm
Is Mesoblast (ASX:MSB) Price Swings Creating A Possible Valuation Opportunity? - Apr 8th, 2026 10:16 am
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation - Apr 8th, 2026 7:07 am
Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - Apr 7th, 2026 9:35 pm